Le Lézard
Classified in: Health
Subjects: VET, ATY

US Navy Veterans Mesothelioma Advocate Urges the Family of a Navy Veteran with Just Diagnosed Mesothelioma to Not Gamble on Compensation and to Call the Lawyers at Danziger & De Llano to Ensure a Top Compensation Result that Might Be Millions


WASHINGTON, June 9, 2022 /PRNewswire/ -- The US Navy Veterans Mesothelioma Advocate is urging the Family of a Navy Veteran who has just been diagnosed with mesothelioma anywhere in the USA to please call the amazing law firm of Danziger & De Llano at 800-864-4000 for a no obligation conversation about financial compensation as well as specifics of how the compensation process works.

The Advocate says, "The law firm of Danziger & De Llano is a national mesothelioma law firm and they have been producing superior results for Navy Veterans nationwide for over two decades. Financial compensation for a Navy Veteran with mesothelioma might be millions of dollars depending on the specifics of how they were exposed to asbestos.

"The reason we have endorsed, and we recommend the law firm of Danziger & De Llano for a Navy Veteran with recently diagnosed mesothelioma anywhere in the nation is because we are certain their team will produce the best possible compensation results. If your husband or dad is a Navy Veteran with recently diagnosed mesothelioma anywhere in the US-before you hire a lawyer to assist with financial compensation, please call the law firm of Danziger & De Llano at 800-864-4000. We are certain you will be very glad you did."  https://meso.dandell.com/

According to the CDC the states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon.

However, based on the calls the US Navy Veterans Mesothelioma Advocate receives a US Navy Veteran who has been diagnosed with mesothelioma could live in any state including New York, Florida, California, Texas, Ohio, Iowa, Indiana, Missouri, North Carolina, Kentucky, Tennessee, Georgia, Alabama, Oklahoma, Arkansas, Kansas, Nebraska, North Dakota, Wyoming, Nevada, Colorado, New Mexico, Utah, Arizona, Idaho, or Alaska.  https://meso.dandell.com/

For more information about mesothelioma, please refer to the National Institutes of Health's web site related to this rare form of cancer: https://www.cancer.gov/types/mesothelioma

Media Contact:
Michael Thomas
202-422-2069
[email protected]

SOURCE US Navy Veterans Mesothelioma Advocate


These press releases may also interest you

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...

at 16:20
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The...

at 16:19
Aflac Incorporated announced today that it will release first quarter 2024 financial results after the market closes on May 1, 2024. At that time, earnings materials, including the quarterly earnings release and financial supplement, will be...

at 16:15
Medpace Holdings, Inc. ("Medpace") today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024. The Company will host a conference call the following morning, Tuesday, April 23, 2024,...

at 16:15
  Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell...



News published on and distributed by: